BioCentury | Mar 3, 2021
Product Development

Verdine’s FogPharma to bring lead cell-permeable peptide into clinic with $107M series C

FogPharma will use its venBio-led $107 million series C round to bring its lead program, a cell-permeable CTNNB1 antagonist, into the clinic for cancer. The company, helmed by Chairman, President...
BioCentury | Jan 5, 2021

Immuneering, Terns, Ikena raise crossover rounds as IPO queue stands to grow again

With crossover investors lining up to participate, biotechs Immuneering, Terns and Ikena each raised rounds that could augur upcoming public offerings. The deals come as a host of biotechs will likely...
BioCentury | Jun 27, 2020
Translation in Brief

Regeneron enhances checkpoint therapy with CD28 bispecifics; plus NIH funds Alzheimer’s brain mapping, Genentech and more

Regeneron combines CD28 bispecifics with PD-1 mAb In its latest paper covering anti-CD28 bispecific antibodies, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) showed in Science Translational Medicine that the bispecifics could boost anti-PD-1 efficacy. Bispecifics against CD28 and...
BioCentury | Apr 5, 2019
Targets & Mechanisms

Breaking up Hippo to tame proliferation

...TEA domain family member 1 TEAD2 - TEA domain family member 2 TEAD3 - TEA domain family member 3...
...STK3) (MST2) Serine/threonine kinase 4 (STK4) (MST1) TEA domain family member 1 (TEAD1) TEA domain family member 2 (TEAD2) TEA domain family member 3 (TEAD3) TEA...
BioCentury | Jan 15, 2019
Distillery Therapeutics


INDICATION: Brain cancer Cell culture experiments suggest inhibiting TEAD4-YAP1 binding interactions with flufenamic acid-based compounds could help treat glioblastoma. Chemical synthesis of analogs of flufenamic acid, which binds TEAD2, in vitro testing and optimization of...
BioCentury | Nov 2, 2018
Targets & Mechanisms

FDA’s pediatric target picks

...12 homolog; TEAD1 -TEA domain family member 1; TEAD2 -TEA domain family member 2; TEAD3 -TEA domain family member 3...
BioCentury | Sep 14, 2017
Targets & Mechanisms

Platelets YAP at cancer

While elevated platelet levels often signify an underlying malignancy, the molecular mechanisms linking the two are not well understood. Now, a team from MD Anderson has shown a well-known, but barely exploited signaling pathway mediates...
Items per page:
1 - 7 of 7